AerSale vs Hudson Technologies
ASLE and HDSN side by side, both in wholesale trade-durable goods. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ASLE and HDSN compare
AerSale is the larger company, worth 1.3 times as much as Hudson Technologies ($231M against $181M).
Hudson Technologies grew revenue faster over the last twelve months (14.3% versus −13.4% for AerSale).
Hudson Technologies keeps more of each dollar of sales as profit, with a net margin of 3.5% compared with −1.2% at AerSale.
Hudson Technologies scores higher on the StockData Score (11 against 3 for AerSale), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ASLE | HDSN |
|---|---|---|
| Size and price | ||
| Market cap | $231M | $181M |
| Share price | $4.83 | $4.31 |
| Change, 1 year | −35.1% | −52.8% |
| Change, 5 years | −78.4% | 13.7% |
| Beta (5Y) | 0.95 | 0.65 |
| Employees | 704 | 281 |
| StockData Score | ||
| Total score | 3 | 11 (better) |
| Valuation score | 1 | 4 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 20.5× |
| P/S | 0.8× | 0.7× (better) |
| P/B | – | 0.7× |
| EV/EBITDA | 16.0× | 10.7× (better) |
| FCF yield | −15.3% (better) | −19.0% |
| Fair value | – | $5.94 |
| Margin of safety | – | 27.4% |
| Growth | ||
| Revenue growth (TTM) | −13.4% | 14.3% (better) |
| Revenue growth, 5Y average | 9.9% | 10.8% (better) |
| Net income growth (TTM) | −158% | −50.4% (better) |
| EPS growth (TTM) | −157% | −47.5% (better) |
| EPS growth, 5Y average | −52.4% | – |
| Profitability | ||
| Gross margin | 28.9% (better) | 23.3% |
| Operating margin | 0.61% | 4.5% (better) |
| Net margin | −1.2% | 3.5% (better) |
| FCF margin | −11.6% (better) | −13.4% |
| Return on equity | – | 3.6% |
| Return on invested capital | – | 3.7% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Net debt / EBITDA | 6.21 | – |
| Current ratio | 3.27 (better) | 3.23 |
| Altman Z-score | 1.61 | 3.54 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | 9.9% |
| Shareholder yield | 0.00% | 9.9% (better) |
| Ownership | ||
| Held by institutions | 64.3% | 75.1% |
| Held by insiders | 91.6% | 14.1% |
| Insider net buying, 12 months | −$109K (better) | −$387K |
| Short interest, % of float | 79.2% | 7.4% |
Go deeper
- ASLE stock overview
- ASLE income statement
- ASLE valuation and score
- HDSN stock overview
- HDSN income statement
- HDSN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.